Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

10.20 -0.66 (-6.08%)

Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Xeris Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference

April 02, 2024

From Xeris Biopharma Holdings, Inc.

Via Business Wire

XERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023 ↗

March 06, 2024

XERS stock results show that Xeris Biopharma Holdings met analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

Via InvestorPlace

Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events

March 06, 2024

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital

March 06, 2024

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Earnings Outlook For Xeris Biopharma Holdings ↗

March 05, 2024

Via Benzinga

Why Xeris Biopharma Shares Are Trading Higher Today ↗

October 16, 2023

Xeris Biopharma Holdings Inc (NASDAQ: XERS) shares are trading higher by around 9% after the

Via Benzinga

Earnings Scheduled For March 6, 2024 ↗

March 06, 2024

Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million.

Via Benzinga

Earnings Outlook For Xeris Biopharma Holdings ↗

August 07, 2023

Via Benzinga

Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

February 28, 2024

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference

February 05, 2024

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

January 10, 2024

Shares of WD-40 Company (NASDAQ: WDFC) rose sharply during Wednesday’s session after the company reported better-than-expected first-quarter results.

Via Benzinga

Morgan Stanley Block Sale Sends Chewy (CHWY) Stock Down ↗

January 10, 2024

Chewy stock is falling on Wednesday after it was announced that Morgan Stanley is handling a block sale of CHWY shares.

Via InvestorPlace

Why Is Xeris Biopharma (XERS) Stock Up 12% Today? ↗

January 10, 2024

Xeris Biopharma stock is rising higher on Wednesday as investors in XERS shares react to a new exclusive worldwide license agreement.

Via InvestorPlace

Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab

January 10, 2024

From Xeris Biopharma Holdings, Inc.

Via Business Wire

7 Small-Cap Stocks to Best Position Your Portfolio for a Strong 2024 ↗

January 08, 2024

Small cap stocks are anticipated to rise by as much as 50% in 2024 as investors look for growth in new areas of the market.

Via InvestorPlace

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

January 05, 2024

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday ↗

January 04, 2024

U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Lamb Weston Holdings, Inc. (NYSE: LW) rose during Thursday’s session following...

Via Benzinga

Topics Stocks

Xeris Biopharma Updates Its Outlook for 2023

January 04, 2024

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 27, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma Reports Third Quarter 2023 Financial Results

November 09, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4 2023

October 16, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Earnings Scheduled For November 9, 2023 ↗

November 09, 2023

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.

Via Benzinga

Xeris Biopharma Announces Private Convertible Note Exchange Transactions

September 27, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris to Participate in the 2023 Cantor Global Healthcare Conference

September 14, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023 ↗

August 28, 2023

Via Benzinga

Xeris to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

August 28, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

$8M Bet On Vicarious Surgical? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying ↗

August 10, 2023

The Dow Jones closed lower by around 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline

August 08, 2023

Dallas, Texas--(Newsfile Corp. - August 8, 2023) - Stonegate is pleased to announce the...

Via Newsfile

Xeris Biopharma Reports Second Quarter 2023 Financial Results

August 08, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma to Report Second Quarter 2023 Financial Results on August 8, 2023

August 01, 2023

From Xeris Biopharma Holdings, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.